Its case is before the U.S
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
Both trials suggest maintenance strategies, such as lower-dose injections or oral therapies, could offer patients more flexible, potentially more convenient options for sustaining weight loss after intensive treatment
The lawsuit claims a 44-year-old woman with a history of diabetes took Ozempic for over one year, stopping in July, at which point she started using Mounjaro
Dehydration exacerbates nausea and other stomach issues
doi: 10.7326/0003-4819-146-7-200704030-00003 78 GutniakMOrskovCHolstJJAhrnBEfendicS